BUSINESSQUARTZ
AstraZeneca stock plunges after late-stage heart drug trial misses its target
AstraZeneca's stock fell sharply after its late-stage heart drug trial for Wainua failed to reduce cardiovascular deaths and recurring heart events, causing a $27 billion drop in market value.
Related Signal
Adjacent reporting
- AstraZeneca stock dives 9% after heart drug trial misses target
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
- Major drugmaker loses $27 billion in market value after failed trial
- Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
- LatAm Pre-Open: Brazil Extends Record Run as Chips Keep Sliding